{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:11:20Z","timestamp":1779329480307,"version":"3.51.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02887-5","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:23:55Z","timestamp":1770117835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipidome remodeling in primary biliary cholangitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Magdalena","family":"Rogalska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Rogalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Andrzejuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"B\u0142achnio-Zabielska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Zabielski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2887_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/17474124.2023.2242771","volume":"17","author":"A Floreani","year":"2023","unstructured":"Floreani A, Gabbia D, De Martin S. Primary biliary cholangitis: primary autoimmune disease or primary secretory defect. Expert Rev Gastroenterol Hepatol. 2023;17:863\u201370.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2887_CR2","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.3748\/wjg.v29.i37.5292","volume":"29","author":"VI Reshetnyak","year":"2023","unstructured":"Reshetnyak VI, Maev IV. New insights into the pathogenesis of primary biliary cholangitis asymptomatic stage. World J Gastroenterol. 2023;29:5292\u2013304.","journal-title":"World J Gastroenterol"},{"key":"2887_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","volume":"11","author":"A Lleo","year":"2017","unstructured":"Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatol Int. 2017;11:485\u201399.","journal-title":"Hepatol Int"},{"key":"2887_CR4","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.3748\/wjg.v11.i36.5706","volume":"11","author":"R Flisiak","year":"2005","unstructured":"Flisiak R, Pelszynska M, Prokopowicz D, Rogalska M, Grygoruk U. High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J Gastroenterol. 2005;11:5706\u20139.","journal-title":"World J Gastroenterol"},{"key":"2887_CR5","first-page":"17071","volume":"135","author":"M Rogalska","year":"2025","unstructured":"Rogalska M, Berkan-Kawi\u0144ska A, Klapaczy\u0144ski J, Musierowicz W, Dobrowolska K, Wawrzynowicz-Syczewska M, et al. Clinical characteristics of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Pol Arch Intern Med. 2025;135:17071.","journal-title":"Pol Arch Intern Med"},{"key":"2887_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.37349\/ei.2024.00163","volume":"4","author":"VI Reshetnyak","year":"2024","unstructured":"Reshetnyak VI, Maev IV. Mechanism of formation and significance of antimitochondrial autoantibodies in the pathogenesis of primary biliary cholangitis. Explor Immunol. 2024;4:624\u201339.","journal-title":"Explor Immunol"},{"key":"2887_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cld.2022.06.003","volume":"26","author":"R Chen","year":"2022","unstructured":"Chen R, Tang R, Ma X, Gershwin ME. Immunologic responses and the pathophysiology of primary biliary cholangitis. Clin Liver Dis. 2022;26:583\u2013611.","journal-title":"Clin Liver Dis"},{"key":"2887_CR8","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ma X, Takahashi A, Vierling JM. Primary biliary cholangitis. Lancet. 2024;404:1053\u201366.","journal-title":"Lancet"},{"key":"2887_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cld.2022.06.001","volume":"26","author":"F Colapietro","year":"2022","unstructured":"Colapietro F, Bertazzoni A, Lleo A. Contemporary epidemiology of primary biliary cholangitis. Clin Liver Dis. 2022;26:555\u201370.","journal-title":"Clin Liver Dis"},{"key":"2887_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cld.2023.06.005","volume":"28","author":"MS Faisal","year":"2024","unstructured":"Faisal MS, Gonzalez HC, Gordon SC. Primary biliary cholangitis: Epidemiology, Diagnosis, and presentation. Clin Liver Dis. 2024;28:63\u201377.","journal-title":"Clin Liver Dis"},{"key":"2887_CR11","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1080\/09168451.2020.1793658","volume":"84","author":"R Sato","year":"2020","unstructured":"Sato R. Recent advances in regulating cholesterol and bile acid metabolism. Biosci Biotechnol Biochem. 2020;84:2185\u201392.","journal-title":"Biosci Biotechnol Biochem"},{"key":"2887_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/flgastro-2018-101124","volume":"10","author":"MI Wah-Suarez","year":"2019","unstructured":"Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol. 2019;10:401\u20138.","journal-title":"Frontline Gastroenterol"},{"key":"2887_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5604\/01.3001.0010.5493","volume":"16","author":"A Di Ciaula","year":"2017","unstructured":"Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ, Portincasa P. Bile acid physiology. Ann Hepatol. 2017;16:4\u201314.","journal-title":"Ann Hepatol"},{"key":"2887_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEG.S360563","volume":"15","author":"M Ahmed","year":"2022","unstructured":"Ahmed M, Functional. Diagnostic and therapeutic aspects of bile. Clin Exp Gastroenterol. 2022;15:105\u201320.","journal-title":"Clin Exp Gastroenterol"},{"key":"2887_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/cells12050792","volume":"12","author":"SO Aseem","year":"2023","unstructured":"Aseem SO, Hylemon PB, Zhou H. Bile acids and biliary fibrosis. Cells. 2023;12:792.","journal-title":"Cells"},{"key":"2887_CR16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/0016-5085(84)90142-2","volume":"87","author":"E Ros","year":"1984","unstructured":"Ros E, Garc\u00eda-Pug\u00e9s A, Reixach M, Cus\u00f3 E, Rod\u00e9s J. Fat digestion and exocrine pancreatic function in primary biliary cirrhosis. Gastroenterology. 1984;87:180\u20137.","journal-title":"Gastroenterology"},{"key":"2887_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ncp.11130","volume":"39","author":"E Omer","year":"2024","unstructured":"Omer E, Chiodi C. Fat digestion and absorption: normal physiology and pathophysiology of malabsorption, including diagnostic testing. Nutr Clin Pract. 2024;39:6\u201316.","journal-title":"Nutr Clin Pract"},{"key":"2887_CR18","first-page":"2226","volume":"93","author":"JK DiBaise","year":"1998","unstructured":"DiBaise JK, Paustian FF. Steatorrhea and weight loss in a 72-year-old man: primary biliary cirrhosis? Celiac disease? Bacterial overgrowth? What else? Am J Gastroenterol. 1998;93:2226\u201330.","journal-title":"Am J Gastroenterol"},{"key":"2887_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/hep.1840050522","volume":"5","author":"SJ Lanspa","year":"1985","unstructured":"Lanspa SJ, Chan AT, Bell JS 3rd, Go VL, Dickson ER, DiMagno EP. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology. 1985;5:837\u201342.","journal-title":"Hepatology"},{"key":"2887_CR20","doi-asserted-by":"publisher","first-page":"e13714","DOI":"10.1111\/eci.13714","volume":"52","author":"W Han","year":"2022","unstructured":"Han W, Huang C, Zhang Q, Tao S, Hu X, Xu J, et al. Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid. Eur J Clin Invest. 2022;52:e13714.","journal-title":"Eur J Clin Invest"},{"key":"2887_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/nu13020540","volume":"13","author":"J Traub","year":"2021","unstructured":"Traub J, Reiss L, Aliwa B, Stadlbauer V. Malnutrition in patients with liver cirrhosis. Nutrients. 2021;13:540.","journal-title":"Nutrients"},{"key":"2887_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172\u201393.","journal-title":"J Hepatol"},{"key":"2887_CR23","doi-asserted-by":"crossref","unstructured":"Wicks C, Bray GP, Williams R. Nutritional assessment in primary biliary cirrhosis: the effect of disease severity. Clin Nutr. 1995;14:29\u201334.","DOI":"10.1016\/S0261-5614(06)80007-5"},{"key":"2887_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/030006059001800405","volume":"18","author":"G Salvioli","year":"1990","unstructured":"Salvioli G, Carati L, Lugli R. Steatorrhoea in cirrhosis: effect of ursodeoxycholic acid administration. J Int Med Res. 1990;18:289\u201397.","journal-title":"J Int Med Res"},{"key":"2887_CR25","doi-asserted-by":"crossref","unstructured":"Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol. 2001;96:2745\u201350.","DOI":"10.1111\/j.1572-0241.2001.04134.x"},{"key":"2887_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cld.2018.03.014","volume":"22","author":"DN Assis","year":"2018","unstructured":"Assis DN. Chronic complications of cholestasis: evaluation and management. Clin Liver Dis. 2018;22:533\u201344.","journal-title":"Clin Liver Dis"},{"key":"2887_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2014.08.001","volume":"438","author":"M Raman","year":"2015","unstructured":"Raman M, Fenton T, Crotty P, Ghosh S, Rioux K, Hundal R. A novel method to identify fat malabsorption: the serum retinyl palmitate test. Clin Chim Acta. 2015;438:103\u20136.","journal-title":"Clin Chim Acta"},{"key":"2887_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1590-8658(03)00078-1","volume":"35","author":"E Solerio","year":"2003","unstructured":"Solerio E, Isaia G, Innarella R, Di Stefano M, Farina M, Borghesio E, et al. Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig Liver Dis. 2003;35:339\u201346.","journal-title":"Dig Liver Dis"},{"key":"2887_CR29","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1172\/JCI117959","volume":"95","author":"CH Janes","year":"1995","unstructured":"Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995;95:2581\u20136.","journal-title":"J Clin Invest"},{"key":"2887_CR30","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3748\/wjg.v24.i31.3513","volume":"24","author":"CJ Danford","year":"2018","unstructured":"Danford CJ, Trivedi HD, Papamichael K, Tapper EB, Bonder A. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018;24:3513\u201320.","journal-title":"World J Gastroenterol"},{"key":"2887_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145\u201372.","journal-title":"J Hepatol"},{"key":"2887_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237\u201367.","journal-title":"J Hepatol"},{"key":"2887_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MED.0000000000000466","volume":"26","author":"T Miida","year":"2019","unstructured":"Miida T, Hirayama S. Controversy over the atherogenicity of lipoprotein-X. Curr Opin Endocrinol Diabetes Obes. 2019;26:117\u201323.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2887_CR34","first-page":"49","volume":"8","author":"A Galoosian","year":"2020","unstructured":"Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: Trends, Epidemiology, Diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 2020;8:49\u201360.","journal-title":"J Clin Transl Hepatol"},{"key":"2887_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265\u20139.","journal-title":"Gut"},{"key":"2887_CR36","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","volume":"103","author":"M Solaymani-Dodaran","year":"2008","unstructured":"Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol. 2008;103:2784\u20138.","journal-title":"Am J Gastroenterol"},{"key":"2887_CR37","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.plipres.2023.101235","volume":"91","author":"V Petrenko","year":"2023","unstructured":"Petrenko V, Sinturel F, Riezman H, Dibner C. Lipid metabolism around the body clocks. Prog Lipid Res. 2023;91:101235.","journal-title":"Prog Lipid Res"},{"key":"2887_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1389200216666151103115454","volume":"17","author":"JJ Marin","year":"2015","unstructured":"Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ. Bile acids in Physiology, pathology and Pharmacology. Curr Drug Metab. 2015;17:4\u201329.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"2887_CR39","first-page":"89","volume":"21","author":"H Gylling","year":"1995","unstructured":"Gylling H, F\u00e4rkkil\u00e4 M, Vuoristo M, Miettinen TA. Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. Hepatology. 1995;21(1):89\u201395. PMID: 7806174.","journal-title":"Hepatology"},{"key":"2887_CR40","doi-asserted-by":"publisher","first-page":"e0178580","DOI":"10.1371\/journal.pone.0178580","volume":"12","author":"Z Li","year":"2017","unstructured":"Li Z, Lin B, Lin G, Wu Y, Jie Y, Li X, et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE. 2017;12:e0178580.","journal-title":"PLoS ONE"},{"key":"2887_CR41","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.1038\/srep13462","volume":"5","author":"E Wunsch","year":"2015","unstructured":"Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempi\u0144ska-Podhorodecka A, Elias E. Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep. 2015;5:13462.","journal-title":"Sci Rep"},{"key":"2887_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"KH Song","year":"2009","unstructured":"Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology. 2009;49:297\u2013305.","journal-title":"Hepatology"},{"key":"2887_CR43","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms19072069","volume":"19","author":"CY Han","year":"2018","unstructured":"Han CY. Update on FXR biology: promising therapeutic target? Int J Mol Sci. 2018;19:2069.","journal-title":"Int J Mol Sci"},{"key":"2887_CR44","first-page":"e31411","volume":"14","author":"A Ahoussougbemey Mele","year":"2022","unstructured":"Ahoussougbemey Mele A, Mahmood R, Ogbuagu H, Fombi J. Hyperlipidemia in the setting of primary biliary cholangitis: A case report and review of management strategies. Cureus. 2022;14:e31411.","journal-title":"Cureus"},{"key":"2887_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","volume":"49","author":"S Fiorucci","year":"2010","unstructured":"Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res. 2010;49:171\u201385.","journal-title":"Prog Lipid Res"},{"key":"2887_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217\u201325.","journal-title":"Cell Metab"},{"key":"2887_CR47","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cgh.2024.01.039","volume":"22","author":"L Zheng","year":"2024","unstructured":"Zheng L, Tian S, Yang C, Li B, Jia G, Liu Y, et al. Hypercholesterolemia is associated with dysregulation of lipid metabolism and poor prognosis in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2024;22:1265\u2013e127419.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2887_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.1840180117","volume":"18","author":"H Hiraoka","year":"1993","unstructured":"Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N, et al. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology. 1993;18:103\u201310.","journal-title":"Hepatology"},{"key":"2887_CR49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12876-021-01974-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol. 2021;21:395.","journal-title":"BMC Gastroenterol"},{"key":"2887_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-19-1592-5_1","volume":"1377","author":"S Deng","year":"2022","unstructured":"Deng S, Xu Y, Zheng L. HDL structure. Adv Exp Med Biol. 2022;1377:1\u201311.","journal-title":"Adv Exp Med Biol"},{"key":"2887_CR51","doi-asserted-by":"publisher","first-page":"602252","DOI":"10.3389\/fendo.2020.602252","volume":"11","author":"A Gonen","year":"2020","unstructured":"Gonen A, Miller YI. From inert storage to biological Activity-In search of identity for oxidized cholesteryl esters. Front Endocrinol (Lausanne). 2020;11:602252.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2887_CR52","doi-asserted-by":"publisher","first-page":"501739","DOI":"10.1155\/2009\/501739","volume":"2009","author":"T Li","year":"2009","unstructured":"Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009;2009:501739.","journal-title":"PPAR Res"},{"key":"2887_CR53","doi-asserted-by":"publisher","first-page":"35660","DOI":"10.1074\/jbc.M113.519116","volume":"288","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Maxwell KN, Sezgin E, Lu M, Liang H, Hancock JF, et al. Bile acids modulate signaling by functional perturbation of plasma membrane domains. J Biol Chem. 2013;288:35660\u201370.","journal-title":"J Biol Chem"},{"key":"2887_CR54","doi-asserted-by":"publisher","first-page":"e100074","DOI":"10.1136\/egastro-2024-100074","volume":"2","author":"T Li","year":"2024","unstructured":"Li T, Hasan MN, Gu L. Bile acids regulation of cellular stress responses in liver physiology and diseases. eGastroenterology. 2024;2:e100074.","journal-title":"eGastroenterology"},{"key":"2887_CR55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1042\/bj1880321","volume":"188","author":"D Billington","year":"1980","unstructured":"Billington D, Evans CE, Godfrey PP, Coleman R. Effects of bile salts on the plasma membranes of isolated rat hepatocytes. Biochem J. 1980;188:321\u20137.","journal-title":"Biochem J"},{"key":"2887_CR56","doi-asserted-by":"publisher","first-page":"117955141987868","DOI":"10.1177\/1179551419878687","volume":"12","author":"L Kattah","year":"2019","unstructured":"Kattah L, G\u00f3mez A, Guti\u00e9rrez S, Puerto K, Moreno-Pallares ED, Jaramillo A, et al. Hypercholesterolemia due to lipoprotein X: case report and thematic review. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419878687.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2887_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clinbiochem.2021.04.017","volume":"94","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wang S, Liang S, Zhang H, Zhang Y, et al. Clinical laboratory characteristics of patients with obstructive jaundice accompanied by dyslipidemia. Clin Biochem. 2021;94:42\u20137.","journal-title":"Clin Biochem"},{"key":"2887_CR58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0004563213478804","volume":"50","author":"MA Crook","year":"2013","unstructured":"Crook MA. Lipoprotein X: clinical implications. Ann Clin Biochem. 2013;50:93\u20134.","journal-title":"Ann Clin Biochem"},{"key":"2887_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.numecd.2018.09.006","volume":"29","author":"R Fellin","year":"2019","unstructured":"Fellin R, Manzato E. Lipoprotein-X Fifty years after its original discovery. Nutr Metab Cardiovasc Dis. 2019;29:4\u20138.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2887_CR60","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3390\/biomedicines10123046","volume":"10","author":"VI Reshetnyak","year":"2022","unstructured":"Reshetnyak VI, Maev IV. Features of lipid metabolism disorders in primary biliary cholangitis. Biomedicines. 2022;10:3046.","journal-title":"Biomedicines"},{"key":"2887_CR61","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1073\/pnas.75.7.3459","volume":"75","author":"TE Felker","year":"1978","unstructured":"Felker TE, Hamilton RL, Havel RJ. Secretion of lipoprotein-X by perfused livers of rats with cholestasis. Proc Natl Acad Sci U S A. 1978;75:3459\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2887_CR62","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1172\/JCI3597","volume":"102","author":"RP Elferink","year":"1998","unstructured":"Elferink RP, Ottenhoff R, van Marle J, Frijters CM, Smith AJ, et al. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest. 1998;102:1749\u201357.","journal-title":"J Clin Invest"},{"key":"2887_CR63","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1172\/JCI108393","volume":"57","author":"E Manzato","year":"1976","unstructured":"Manzato E, Fellin R, Baggio G, Walch S, Neubeck W, et al. Formation of lipoprotein-X. Its relationship to bile compounds. J Clin Invest. 1976;57:1248\u201360.","journal-title":"J Clin Invest"},{"issue":"8 Pt A","key":"2887_CR64","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.bbalip.2016.04.016","volume":"1861","author":"S Heimerl","year":"2016","unstructured":"Heimerl S, Boettcher A, Kaul H, Liebisch G. Lipid profiling of lipoprotein X: implications for dyslipidemia in cholestasis. Biochim Biophys Acta. 2016;1861(8 Pt A):681\u20137.","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20132","key":"2887_CR65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1023\/A:1006865420286","volume":"175","author":"EG Lynn","year":"1997","unstructured":"Lynn EG, Choy PC, Magil A. Uptake and metabolism of lipoprotein-X in mesangial cells. Mol Cell Biochem. 1997;175(1\u20132):187\u201394.","journal-title":"Mol Cell Biochem"},{"key":"2887_CR66","doi-asserted-by":"publisher","first-page":"232470962210894","DOI":"10.1177\/23247096221089488","volume":"10","author":"E Petrie","year":"2022","unstructured":"Petrie E, Hoppmann NA, Wilcox CM, Al Diffalha S, Gray ME. Gastric xanthomatosis secondary to lipoprotein X in primary biliary cholangitis. J Investig Med High Impact Case Rep. 2022;10:23247096221089488.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2887_CR67","first-page":"283","volume":"39","author":"A \u0106wikli\u0144ska","year":"2020","unstructured":"\u0106wikli\u0144ska A, Mickiewicz A, Kowalski R, Kortas-Stempak B, Kuchta A, et al. Detection of lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia. J Med Biochem. 2020;39:283\u20139.","journal-title":"J Med Biochem"},{"key":"2887_CR68","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","volume":"194","author":"A Sorokin","year":"2007","unstructured":"Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194:293\u20139.","journal-title":"Atherosclerosis"},{"key":"2887_CR69","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jacl.2020.08.012","volume":"14","author":"Z Lian","year":"2020","unstructured":"Lian Z, Saeed A, Peng X, Perrard XD, Jia X, et al. Monocyte phenotyping and management of lipoprotein X syndrome. J Clin Lipidol. 2020;14:850\u20138.","journal-title":"J Clin Lipidol"},{"key":"2887_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jacl.2016.10.013","volume":"11","author":"L Suzuki","year":"2017","unstructured":"Suzuki L, Hirayama S, Fukui M, Sasaki M, Hiroi S, et al. Lipoprotein-X in cholestatic patients causes Xanthomas and promotes foam cell formation in human macrophages. J Clin Lipidol. 2017;11:110\u20138.","journal-title":"J Clin Lipidol"},{"key":"2887_CR71","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1136\/gut.2005.079814","volume":"55","author":"M Allocca","year":"2006","unstructured":"Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006;55:1795\u2013800.","journal-title":"Gut"},{"key":"2887_CR72","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.clinre.2024.102321","volume":"48","author":"Y Liang","year":"2024","unstructured":"Liang Y, Li J, Zhang Z, Jiang T, Yang Z. Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk. Clin Res Hepatol Gastroenterol. 2024;48:102321.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2887_CR73","doi-asserted-by":"publisher","first-page":"102419","DOI":"10.1016\/j.clinre.2024.102419","volume":"48","author":"YL Lin","year":"2024","unstructured":"Lin YL, Yao T, Wang YW, Yu JS, Zhen C, Lin JF, et al. Association between primary biliary cholangitis with diabetes and cardiovascular diseases: A bidirectional multivariable Mendelian randomization study. Clin Res Hepatol Gastroenterol. 2024;48:102419.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2887_CR74","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1572-0241.2008.01888.x","volume":"103","author":"A Floreani","year":"2008","unstructured":"Floreani A, Variola A, Niro G, Premoli A, Baldo V, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103:1959\u201365.","journal-title":"Am J Gastroenterol"},{"key":"2887_CR75","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","volume":"45","author":"PY Chang","year":"2004","unstructured":"Chang PY, Lu SC, Su TC, Chou SF, Huang WH, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116\u201322.","journal-title":"J Lipid Res"},{"key":"2887_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.14218\/JCTH.2017.00064","volume":"6","author":"D Suraweera","year":"2018","unstructured":"Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of cardiovascular events in patients with primary biliary Cholangitis - Systematic review. J Clin Transl Hepatol. 2018;6:119\u201326.","journal-title":"J Clin Transl Hepatol"},{"key":"2887_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MCG.0000000000000029","volume":"49","author":"A Floreani","year":"2015","unstructured":"Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L, et al. Metabolic syndrome associated with primary biliary cirrhosis. J Clin Gastroenterol. 2015;49:57\u201360.","journal-title":"J Clin Gastroenterol"},{"key":"2887_CR78","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrm.2017.107","volume":"19","author":"YA Hannun","year":"2018","unstructured":"Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19:175\u201391.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2887_CR79","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1515\/hsz-2014-0296","volume":"396","author":"H Nojima","year":"2015","unstructured":"Nojima H, Freeman CM, Gulbins E, Lentsch AB. Sphingolipids in liver injury, repair and regeneration. Biol Chem. 2015;396:633\u201343.","journal-title":"Biol Chem"},{"key":"2887_CR80","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","volume":"27","author":"M Mar\u00ed","year":"2007","unstructured":"Mar\u00ed M, Fern\u00e1ndez-Checa JC. Sphingolipid signalling and liver diseases. Liver Int. 2007;27:440\u201350.","journal-title":"Liver Int"},{"key":"2887_CR81","doi-asserted-by":"publisher","first-page":"106399","DOI":"10.1016\/j.prostaglandins.2019.106399","volume":"147","author":"A Mikucka-Niczyporuk","year":"2020","unstructured":"Mikucka-Niczyporuk A, Pierzynski P, Lemancewicz A, Kosinski P, Charkiewicz K, et al. Role of sphingolipids in the pathogenesis of intrahepatic cholestasis. Prostaglandins Other Lipid Mediat. 2020;147:106399.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2887_CR82","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/nu17071097","volume":"17","author":"M Rogalska","year":"2025","unstructured":"Rogalska M, B\u0142achnio-Zabielska A, Zabielski P, Janica JR, Roszczyc-Owsiejczuk K, et al. Acylcarnitine and free fatty acid profiles in primary biliary cholangitis: associations with fibrosis and inflammation. Nutrients. 2025;17:1097.","journal-title":"Nutrients"},{"key":"2887_CR83","doi-asserted-by":"publisher","first-page":"42502","DOI":"10.1038\/s41598-025-26502-2","volume":"15","author":"M Rogalska","year":"2025","unstructured":"Rogalska M, B\u0142achnio-Zabielska A, Zabielski P, Janica J, Roszczyc-Owsiejczuk K, et al. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep. 2025;15:42502.","journal-title":"Sci Rep"},{"key":"2887_CR84","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362\u20135.","journal-title":"Science"},{"key":"2887_CR85","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. Identification of a nuclear receptor that is activated by Farnesol metabolites. Cell. 1995;81:687\u201393.","journal-title":"Cell"},{"key":"2887_CR86","doi-asserted-by":"publisher","first-page":"111618","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:111618.","journal-title":"Mol Cell Endocrinol"},{"key":"2887_CR87","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1053\/j.gastro.2015.02.037","volume":"148","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA. Targeting the FXR nuclear receptor to treat liver disease. Gastroenterology. 2015;148:704\u20136.","journal-title":"Gastroenterology"},{"key":"2887_CR88","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","volume":"3","author":"M Almeqdadi","year":"2023","unstructured":"Almeqdadi M, Gordon FD, Farnesoid X, Receptor Agonists. A promising therapeutic strategy for Gastrointestinal diseases. Gastro Hep Adv. 2023;3:344\u201352.","journal-title":"Gastro Hep Adv"},{"key":"2887_CR89","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/347645a0","volume":"347","author":"I Issemann","year":"1990","unstructured":"Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645\u201350.","journal-title":"Nature"},{"key":"2887_CR90","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/cells9112367","volume":"9","author":"N Wagner","year":"2020","unstructured":"Wagner N, Wagner KD. The role of PPARs in disease. Cells. 2020;9:2367.","journal-title":"Cells"},{"key":"2887_CR91","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","volume":"6","author":"F Colapietro","year":"2023","unstructured":"Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new Tales. J Transl Autoimmun. 2023;6:100188.","journal-title":"J Transl Autoimmun"},{"key":"2887_CR92","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69:394\u2013419.","journal-title":"Hepatology"},{"key":"2887_CR93","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jacc.2008.04.052","volume":"52","author":"CM Ballantyne","year":"2008","unstructured":"Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between Apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring effective reductions in cholesterol using Rosuvastatin) trial. J Am Coll Cardiol. 2008;52:626\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"2887_CR94","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","volume":"42","author":"M Del Puppo","year":"2001","unstructured":"Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, et al. Cholesterol metabolism in primary biliary cirrhosis during Simvastatin and UDCA administration. J Lipid Res. 2001;42:437\u201341.","journal-title":"J Lipid Res"},{"key":"2887_CR95","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1521\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2887_CR96","doi-asserted-by":"publisher","first-page":"924","DOI":"10.4254\/wjh.v8.i22.924","volume":"8","author":"K Nemes","year":"2016","unstructured":"Nemes K, \u00c5berg F, Gylling H, Isoniemi H. Cholesterol metabolism in cholestatic liver disease and liver transplantation: from molecular mechanisms to clinical implications. World J Hepatol. 2016;8:924\u201332.","journal-title":"World J Hepatol"},{"key":"2887_CR97","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases. Hepatology. 2022;75:1012\u20133.","journal-title":"Hepatology"},{"key":"2887_CR98","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","volume":"62","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62:635\u201343.","journal-title":"Hepatology"},{"key":"2887_CR99","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/hep.1840170408","volume":"17","author":"RE Poupon","year":"1993","unstructured":"Poupon RE, Ouguerram K, Chr\u00e9tien Y, Verneau C, Eschw\u00e8ge E, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology. 1993;17:577\u201382.","journal-title":"Hepatology"},{"key":"2887_CR100","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, et al. A Placebo-Controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u201343.","journal-title":"N Engl J Med"},{"key":"2887_CR101","doi-asserted-by":"publisher","first-page":"865","DOI":"10.21037\/hbsn-2025-329","volume":"14","author":"P Rogalski","year":"2025","unstructured":"Rogalski P, Rogalska M. Second-line therapies in PBC-related cirrhosis: balancing efficacy and safety. Hepatobiliary Surg Nutr. 2025;14:865\u20138.","journal-title":"Hepatobiliary Surg Nutr"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02887-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02887-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:03:22Z","timestamp":1772625802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02887-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2887"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02887-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}